Cargando…
Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
SIMPLE SUMMARY: The introduction of JAK inhibitors has provided objective benefits to many patients with myeloproliferative neoplasms. However, the overall efficacy of these drugs is limited and improved therapeutic options are required. Epigenetic dysregulation is increasingly observed to play a ro...
Autores principales: | Greenfield, Graeme, McPherson, Suzanne, Smith, James, Mead, Adam, Harrison, Claire, Mills, Ken, McMullin, Mary Frances |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563593/ https://www.ncbi.nlm.nih.gov/pubmed/32962027 http://dx.doi.org/10.3390/cancers12092669 |
Ejemplares similares
-
Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017) -
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2018) -
Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021) -
Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023) -
Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series
por: Greenfield, Graeme, et al.
Publicado: (2018)